TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

T. L. Lasho, A. Tefferi, J. D. Hood, S. Verstovsek, D. G. Gilliland, A. Pardanani

Research output: Contribution to journalArticle

88 Scopus citations
Original languageEnglish (US)
Pages (from-to)1790-1792
Number of pages3
JournalLeukemia
Volume22
Issue number9
DOIs
StatePublished - Jan 1 2008

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this